Objective: To systematically evaluate the safety and efficacy of modified Sijunzi Tang in treating chronic atrophic gastritis. Method: We searched Cochrane Library

Pubmed

Embase

CNKI

CBM

VIP and Wanfang Data through computer for data as at June 14

2015.All of randomized controlled trials(RCTs) of modified Sijunzi Tang in treating chronic atrophic gastritis were searched

relevant core journals were manually searched

and research literatures included in the RCTs were also traced. Two researchers independently conducted the strict quality evaluation and data extraction for the included studies on the basis of the Cochrane system assessor handbook 5.1

and made a Meta-analysis by using RevMan 5.3 software. Result: Totally 7 RCTs involving 577 patients were included into the study. The Meta-analysis results showed that compared with western medicine

modified Sijunzi Tang can significantly improve the clinical efficacy in treating patients with chronic atrophic gastritis

with the effect size and 95% confidence interval of[OR=4.10

95%CI(2.57

6.53)

P<0.00001]

merge test analysis result of Z=5.94

and statistically significant differences in both groups. In adverse reaction

only one study showed dry mouth in 1 case

dizziness in 2 cases

1 case of diarrhea in the control group were recovered with no need of treatment. Observation group showed no adverse reactions

with a significant difference in the incidence of adverse reactions between the two groups(P<0.05). Conclusion: According to the Meta-analysis on the seven included CRTs

modified Sijunzi Tang in treating chronic atrophic gastritis can effectively improve the clinical effective rate. However

due to the low quality and small sample size of included RCTs in this study

more multicenter

double-blind RCTs with a large sample size are required to further verify the efficacy and safety of modified Sijunzi Tang in treating chronic atrophic gastritis.